Abstract
Alzheimer’s disease (AD) and Parkinson's disease (PD) are the two most widespread neurological disorders (NDs) characterized by degeneration of cognitive and motor functions due to malfunction and loss of neurons in the central nervous system (CNS). Numerous evidences have established the role of neuroinflammation in the AD and PD pathology. The inflammatory components such as microglia, astrocytes, complement system and cytokines are linked to neuroinflammation in the CNS. More specifically, cytokines have been found to play a central role in the neuroinflammation of AD and PD. A number of studies have demonstrated abnormally elevated levels of inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF) in AD and PD patients. Activated microglial cells have been shown to be involved in the secretion of pro-inflammatory cytokines such as IL-1, IL-6, TNF-α and transforming growth factor-β, thereby contributing towards the progress of NDs. In addition, studies on AD pathogenesis have demonstrated that microglia produce beta-amyloid protein (Aβ), which by itself is pro-inflammatory and causes activation of several inflammatory components. Similarly, chronic inflammation caused by microglial cells is the fundamental process involved in the destruction of neurons associated with dopamine (DA)-production in the brain of PD patients. Hence, there is a need to explore the key inflammatory components in AD and PD pathogenesis in order to fully understand the root cause and establish a substantial link between these two disorders. Such knowledge will help in better management and treatment of AD and PD.
Keywords: Alzheimer's disease, Parkinson's disease, inflammation, cytokines, interleukin-1, interleukin-6, tumor necrosis factor-α, transforming growth factor-β, microglia.
Current Pharmaceutical Design
Title:Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Volume: 22 Issue: 5
Author(s): Qamre Alam, Mohammad Zubair Alam, Gohar Mushtaq, Ghazi A. Damanhouri, Mahmood Rasool, Mohammad Amjad Kamal and Absarul Haque
Affiliation:
Keywords: Alzheimer's disease, Parkinson's disease, inflammation, cytokines, interleukin-1, interleukin-6, tumor necrosis factor-α, transforming growth factor-β, microglia.
Abstract: Alzheimer’s disease (AD) and Parkinson's disease (PD) are the two most widespread neurological disorders (NDs) characterized by degeneration of cognitive and motor functions due to malfunction and loss of neurons in the central nervous system (CNS). Numerous evidences have established the role of neuroinflammation in the AD and PD pathology. The inflammatory components such as microglia, astrocytes, complement system and cytokines are linked to neuroinflammation in the CNS. More specifically, cytokines have been found to play a central role in the neuroinflammation of AD and PD. A number of studies have demonstrated abnormally elevated levels of inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF) in AD and PD patients. Activated microglial cells have been shown to be involved in the secretion of pro-inflammatory cytokines such as IL-1, IL-6, TNF-α and transforming growth factor-β, thereby contributing towards the progress of NDs. In addition, studies on AD pathogenesis have demonstrated that microglia produce beta-amyloid protein (Aβ), which by itself is pro-inflammatory and causes activation of several inflammatory components. Similarly, chronic inflammation caused by microglial cells is the fundamental process involved in the destruction of neurons associated with dopamine (DA)-production in the brain of PD patients. Hence, there is a need to explore the key inflammatory components in AD and PD pathogenesis in order to fully understand the root cause and establish a substantial link between these two disorders. Such knowledge will help in better management and treatment of AD and PD.
Export Options
About this article
Cite this article as:
Alam Qamre, Alam Zubair Mohammad, Mushtaq Gohar, Damanhouri A. Ghazi, Rasool Mahmood, Kamal Amjad Mohammad and Haque Absarul, Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines, Current Pharmaceutical Design 2016; 22 (5) . https://dx.doi.org/10.2174/1381612822666151125000300
DOI https://dx.doi.org/10.2174/1381612822666151125000300 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
CNS & Neurological Disorders - Drug Targets Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Mini-Reviews in Medicinal Chemistry Overview and Findings from the Rush Memory and Aging Project
Current Alzheimer Research Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders
CNS & Neurological Disorders - Drug Targets Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) <i>Cannabis Sativa</i> L. Flower and Bud Extracts Inhibited <i>In vitro</i> Cholinesterases and β-Secretase Enzymes Activities: Possible Mechanisms of Cannabis Use in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Cytokines in Neuroinflammation and Alzheimers Disease
Current Drug Targets Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Impact of the CD40-CD40L Dyad in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology